ReviewCurrent opinion in oncology2014
Metabolic control of tumour progression and antitumour immunity.
Review in Current opinion in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Dynamic remodeling of amino acid metabolism in tumor-associated macrophages: Fueling immunosuppression, reshaping tumor niches, and unlocking metabolic checkpoints.Journal of advanced research · 2026Review
- Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.International journal of nanomedicine · 2022Article
- E-cadherin on epithelial-mesenchymal transition in thyroid cancer.Cancer cell international · 2021Review
- Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models.Cancer & metabolism · 2021Article
- Association Between Succinate Receptor SUCNR1 Expression and Immune Infiltrates in Ovarian Cancer.Frontiers in molecular biosciences · 2020Article
- Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study.Cancer management and research · 2020Article
- Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome.Cancer management and research · 2020Article
- Sexual dimorphism and the role of estrogen in the immune microenvironment of liver metastases.Nature communications · 2019Article
- IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis.Cancer research · 2019Article
- Targeting amino acid metabolism in cancer growth and anti-tumor immune response.World journal of biological chemistry · 2015Review
- Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA.European journal of immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewLoss of cell growth control is not sufficient to explain why tumours form as the immune system recognizes many malignant cells and keeps them in check. The local inflammatory microenvironment is a pivotal factor in tumour formation, as tumour-associated inflammation actively suppresses antitumour immunity. The purpose of this review is to evaluate emerging evidence that amino acid catabolism is a key feature of tumour-associated inflammation that supports tumour progression and immune resistance to therapy. RECENT
findingsEnhanced amino acid catabolism in inflammatory tumour microenvironments correlates with carcinogen resistance and immune regulation mediated by tumour-associated immune cells that protect tumours from natural and vaccine-induced immunity. Interfering with metabolic pathways exploited by tumours is a promising antitumour strategy, especially when combined with other therapies. Moreover, molecular sensors that evolved to detect pathogens may enhance evasion of immune surveillance to permit tumour progression. SUMMARY: Innate immune sensing that induces amino acid catabolism in tumour microenvironments may be pivotal in initiating and sustaining local inflammation that promotes immune resistance and attenuates antitumour immunity. Targeting molecular sensors that mediate these metabolic changes may be an effective strategy to enhance antitumour immunity that prevents tumour progression, as well as improving the efficacy of cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.